Compare General Mills, Inc. (GIS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Tango Therapeutics Inc. — how do they compare? General Mills, Inc. trades at $32.5 (market cap $17.17B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: General Mills, Inc. is far larger — about 4.6× Tango Therapeutics Inc.'s market cap, and General Mills, Inc. pays a 7.6% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 107 Days and Tango Therapeutics Inc. for 0 Days on average.
| GIS | TNGX | |
|---|---|---|
Market Cap | $17.17B | $3.74B |
Volume | 12,286,564 | 3,438,781 |
Sector | Consumer Staples | Health |
52-Week High | $49.18 | $32.90 |
52-Week Low | $31.67 | $7.50 |
Typical Hold Time | 107 Days | 0 Days |
Enterprise Value | $30.35B | $2.76B |
Dividend Yield | 7.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $31.83, down 2.66% amid bearish technical signals and negative profitability metrics. The stock shows mixed earnings performance with a recent Q2 beat but Q4 miss, while revenue has declined from $20.1B in 2023 to $19.5B in 2025. Analyst consensus remains cautious with 61% hold ratings, though the $36 price target suggests 13% upside potential. Recent CEO transition and dividend declaration provide stability signals despite profitability challenges.
The outlook remains challenged by declining margins and negative ROE/ROA, though attractive valuation (P/E 9.2) and dividend yield offer value appeal. Key risks include continued revenue pressure, margin compression, and high debt levels at 45% of assets. Upside depends on successful execution of the $3B savings plan and international growth initiatives.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
